Autotransfusion Devices Global Market Report 2024

The autotransfusion devices market has grown strongly in recent years. It will grow from $1.17 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The expansion observed in the historical period can be attributed to several factors, including a rise in surgical procedures, increased prevalence of cardiovascular diseases, the surge in orthopedic surgeries and joint replacements, a heightened focus on patient safety, and concerted efforts aimed at reducing blood transfusion costs.

The autotransfusion devices market is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. In the forecast period, the anticipated growth is linked to the expanding geriatric population, the proliferation of ambulatory surgical centers, a heightened focus on blood conservation within obstetrics, and increased adoption in developing healthcare markets.

The anticipated rise in cardiovascular diseases (CVDs) is set to propel growth within the autotransfusion device market. CVDs encompass a spectrum of heart and blood vessel disorders, and autotransfusion devices play a crucial role in reducing reliance on allogeneic blood transfusions. These devices facilitate reinfusion of a patient's own blood, mitigating the risks associated with donor blood transfusions. Notably, the American Heart Association's Heart Disease and Stroke Statistics-2022 Update report highlighted CVDs as the foremost global cause of mortality, claiming approximately 17.9 million lives annually, underscoring the market's trajectory.

The escalating demand for blood conservation is expected to be a significant driver for the autotransfusion devices market. Within surgical contexts, blood conservation aims to avoid allogeneic blood transfusions during and post-surgery to enhance patient outcomes and safeguard their well-being. Autotransfusion devices effectively minimize blood loss during surgical procedures, contributing to improved patient recovery. As per the June 2023 report by the World Health Organization, a substantial percentage of reporting countries, accounting for 73% or 125 out of 171, have implemented national blood policies. This indicates a widespread initiative toward blood conservation, affirming the market's growth.

Major players within the autotransfusion devices market are actively pursuing strategic partnerships to elevate controlled substance management. Collaborative ventures enable pooling of expertise and resources to develop advanced technologies and innovative solutions specific to autotransfusion devices. A case in point is the November 2021 collaboration between Omnicell, a US-based healthcare company, and Fresenius Kabi, a Germany-based pharmaceutical company. This partnership is geared towards enhancing controlled substance management, including autotransfusion devices, ensuring compliance with regulations and prioritizing patient safety.

Innovations in product development, particularly the integration of next-generation intelligent control software, signify a pivotal focus among major autotransfusion device companies. This software upgrade, known as Intelligent Control, introduces significant enhancements aimed at simplifying operations, thereby enhancing efficiency and user experience. For instance, Haemonetics, a US-based healthcare company, received FDA 510(k) clearance for its next-generation Intelligent Control software in March 2023, specifically designed for the Cell Saver Elite+ autotransfusion system. This advancement in software technology reaffirms Haemonetics' commitment to pioneering solutions for improved patient outcomes in surgeries involving medium to high blood loss scenarios, spanning cardiac, orthopedic, trauma, transplant, vascular, and OBGYN surgeries.

In October 2021, Morgan Stanley Infrastructure Inc., a prominent US-based investment management and infrastructure firm, completed the acquisition of Specialty Care Inc. for an undisclosed sum. This strategic move aimed to enhance patient care outcomes and marked Morgan Stanley Infrastructure's initial venture into the healthcare sector. Specialty Care Inc. is a US-based provider specializing in autotransfusion system services.

Major companies operating in the autotransfusion devices market report are Becton Dickinson And Company, Medtronic plc, LivaNova plc, Haemonetics Corporation, Fresenius SE & Co KGaA, Terumo Corporation, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec, B. Braun Melsungen AG, GE HealthCare Technologies Inc., Cerus Corporation, Stryker Corporation, Atrium Medical Technologies, Brightwake Ltd., Getinge AB, Advancis Surgical, Beijing ZKSK Technology Co. Ltd., Braile Biomédica, Redax S.p.A., Teleflex Incorporated, Zimmer Biomet Holdings Inc., Gen World Medical Devices Corporation, Soma Technology International LLC, ProCell Surgical Inc., Beijing Jingjing Medical Equipment Co. Ltd., Johnson & Johnson Inc., Sorin Group, Baxter International Inc., Dideco, Nipro Corporation, Advantech Wireless Technologies Inc.

North America was the largest region in the autotransfusion devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global autotransfusion devices market during the forecast period. The regions covered in the autotransfusion devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autotransfusion devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary components of autotransfusion devices encompass autotransfusion systems, consumables, and accompanying accessories. Autotransfusion systems encompass both medical devices and methodologies enabling patients to receive their own blood for transfusions, negating the need for external donor blood. They serve diverse medical applications such as cardiovascular, orthopedic, neurological, obstetrics, gynecology surgeries, among others, and cater to various end-users including hospitals, specialized clinics, and other medical facilities.

The autotransfusion devices market research report provides autotransfusion devices optical components market statistics, including autotransfusion devices optical components industry global market size, regional shares, competitors with a autotransfusion devices optical components market share, detailed autotransfusion devices optical components market segments, market trends and opportunities, and any further data you may need to thrive in the autotransfusion devices optical components industry. This autotransfusion devices optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autotransfusion devices market consists of sales of on-pump transfusion devices and off-pump transfusion devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.